NANO EGG obtains a patent for “a novel low-molecular-weight drug for the treatment of atopic dermatitis”
Invention of a composition for treating or preventing atopic dermatitis
Based on the concept of “Everything comes from dermatology”, we aim to realize “needle-free medical care” centered on DDS (drug delivery system) technology for the skin, and are involved in the development of research reagents and cosmetics at medical institutions. The company Nano Egg (headquartered in Minato-ku, Tokyo, Representative Director Yoko ) has invented and obtained a patent for a “new low-molecular therapeutic drug for the treatment of atopic
Atopic dermatitis is a condition in which an excessive immune response weakens the skin’s barrier function, causing skin inflammation and severe itching, which repeats getting better and worse.
Until now, the basic treatment has been skin care such as applying anti-inflammatory agents such as steroids and tacrolimus ointment, which is an immunosuppressant, and moisturizing.
However, since 2018, the mechanism of itching has been clarified, and new drugs have been created one after another due to advances in understanding the pathology.
Treatment options are said to be expanding.
However, although various theories have been proposed about the detailed onset mechanism, it has not been clarified yet, and the current situation is that no fundamental treatment method has been discovered.
Yoko , Ph.D., the representative of Nano Egg and the general manager of the Research and Development Division, has set her mission as a researcher to elucidate the onset mechanism of atopic dermatitis and develop new technologies based on her experience of worrying about her own child’s atopic care. I have been engaged in the research and development of therapeutic drugs.
As a result of intensive research, Nano Egg focused on adrenergic receptor agonists.
We discovered that it was effective in treating atopic dermatitis, and invented and obtained a patent for a “composition for treating or preventing atopic dermatitis.”
[Skin response to adrenergic receptors]
■Skin cells have the ability to synthesize adrenaline, which is thought to be involved in skin homeostasis.
■In fact, it has been reported that blockers of adrenergic receptors, especially β2, accelerate the recovery of skin barrier function in the skin of healthy individuals (1)(2).
■In atopic patients, abnormal expression of enzymes involved in the production and degradation of noradrenaline and adrenaline has been reported, and an increase in blood noradrenaline and a decrease in adrenaline have been confirmed (1).
■It has also been reported that some patients have mutations in the adrenergic receptor gene and are less responsive to adrenaline (1). These findings suggest that adrenergic receptors are strongly involved in disease.
Therefore, Nanoeg conducted evaluations of adrenergic receptor agonists (agonists) and blockers (antagonists).
We have proven that agonists have therapeutic effects, and have also found that molecular structures with adrenaline-like skeletons can be candidates for the treatment of atopic dermatitis.
In this way, Nano Egg was granted a patent as a “new
low-molecular-weight drug for the treatment of atopic dermatitis.” [Outline of the invention]
■ Patent number: Patent application 2020-521781
■ Invention title: Composition for treating or preventing atopic dermatitis In the future, we will analyze in detail the mechanism by which the drug exerts its therapeutic effect, and aim to develop a more effective treatment for atopic dermatitis.
(1) J. Invest. Dermatol. 2006 Sep;126(9):1948-65.
(2) J. Invest. Dermatol. 2003 Jul;121(1):142-8.
[About Nano Egg Co., Ltd.]
Founded in 2006 from the DDS laboratory at the Research Center for Intractable Diseases, St. Marianna University School of Medicine. Promoting DDS (drug delivery system), a technology that allows highly useful drugs with few side effects to act efficiently where they are needed, and drug discovery research for intractable skin diseases. Research into the cause of atopic dermatitis, a new treatment aimed at complete cure, and the development of a “needle-free” vaccine that can be simply applied or applied to the skin. I am aiming.
Company name: Nano Egg Co., Ltd.
Representative: Representative Director Yoko
Head office: 7-1-15 Akasaka, Minato-ku, Tokyo Atom Aoyama Tower 5F Laboratory location: 3-25-14 Tonomachi, Kawasaki Ward, Kawasaki City, Kanagawa Prefecture Nanomedicine Innovation Center 4F
Established: April 2006
Business: R&D of pharmaceuticals, development and sales of quasi-drugs and cosmetics, sales of pharmaceutical bases and raw materials for cosmetics
Corporate site: https://www.nanoegg.co.jp/
Nanoegg Online Shop: https://www.nanoegg.jp/
Details about this release: